Related Experiment Videos
Cytokine modified tumor vaccines.
Todd D Armstrong1, Elizabeth M Jaffee
1Bunting-Blaustein Cancer Research Building, Room 4M86, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA.
Surgical Oncology Clinics of North America
|December 19, 2002
Summary
The immune system can fight tumors, but cancer can suppress this response. New techniques identify tumor antigens, and some therapies may boost anti-tumor immunity.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- The immune system possesses the capacity for tumor recognition.
- Tumorigenesis can induce active immune tolerance, hindering anti-tumor responses.
- The identification of tumor antigens is expanding due to advancements in technology.
Purpose of the Study:
- To explore the complexities of tumor immunology and immune tolerance.
- To review the current understanding of tumor antigen discovery.
- To assess the clinical efficacy of tumor vaccines and potential synergistic therapies.
Main Methods:
- Review of current literature on tumor immunology and antigen identification.
- Analysis of clinical trial data for genetically modified tumor vaccines.
- Investigation into the immunomodulatory effects of chemotherapeutic agents.
Main Results:
- While tumor vaccines often elicit immune responses like delayed-type hypersensitivity (DTH), clinical responses are infrequent.
- The number of identified tumor antigens is increasing with novel techniques.
- Certain chemotherapeutic agents demonstrate potential to augment the immune effects of tumor vaccines.
Conclusions:
- Despite immune recognition, tumors can evade immune surveillance through active tolerance.
- Advancements in tumor antigen identification are crucial for developing targeted therapies.
- Combination strategies involving tumor vaccines and specific chemotherapeutics may improve clinical outcomes by enhancing anti-tumor immunity.